06.08.2021
DDT COA #000119: PROMIS® Pediatric Chronic Kidney Disease Short Form- Sleep Disturbance
06.08.2021
FDA approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with type 1 plasminogen deficiency, also referred to as hypoplasminogenemia.
06.08.2021
Clinical Outcome Assessments (COA) Qualification Submissions
Office of Drug Evaluation (ODE) III
Division of Gastroenterology and Inborn Error Products (DGIEP)

DDT COA Number
DDT COA #000092
06.08.2021
DDT COA #000093: PROMIS® Pediatric Crohn’s Disease Short Form- Pain Interference
06.08.2021
Finished Pharmaceuticals/Unapproved New Drug/Misbranded
06.08.2021
Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated
06.08.2021
After COVID-19 spotlighted supply chain weaknesses, Biden unveils plan to resurrect U.S. drug manufacturing fkansteiner Tue, 06/08/2021 - 09:27
06.08.2021
Incyte the latest to fall victim to JAK scrutiny as FDA pushes back Jakafi review in GVHD aliu Tue, 06/08/2021 - 09:45
06.08.2021
On a vaccine roll, Pfizer scores FDA nod for Prevnar 13 follow-up ahead of rival Merck kdunleavy Tue, 06/08/2021 - 11:51